Anti-pyroglutamate-3 Aβ immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of Aβ amyloidosis

Liao F
Abbvie
June 2, 2025
Acta Neuropathol
https://pubmed.ncbi.nlm.nih.gov/40455292

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/40455292

Research summary

This study evaluates a monoclonal antibody targeting pyroglutamate-modified Aβ (pGlu3-Aβ), demonstrating reduced amyloid plaque load, enhanced microglial engagement, and preserved synaptic integrity in Alzheimer’s disease models.

Key outcome of the study

pGlu3-Aβ immunotherapy reduces plaque load, activates microglia, and protects synapses, suggesting therapeutic potential in AD.

Model

Transgenic hAPP mouse crossed with genOway’s Cx3cr1-CreERT2-tdTomato line for microglial lineage tracing and activation analysis.

TARGET:
APP, Cx3cr1
Amyloid beta precursor protein, CX3C chemokine receptor 1

Keywords

Alzheimer’s disease, Neuroinflammation, Microglial activation, Immunotherapy

Technical specifications

Humanized APP model, Inducible CreERT2, tdTomato reporter, Microglial tracing, Knockin at endogenous Cx3cr1 locus

Related products

Catalogue product

No items found.

Customized product

Reporter KI mouse

Use a reporter mouse Knockin for in vivo monitoring of transcriptional promoter activity, protein localization, cell trafficking, etc.

Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe